Ginkgo Bioworks Holdings Inc vs Centrus Energy Corp — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.11 (market cap $590.53M), while Centrus Energy Corp trades at $153.59 (market cap $3.14B). The key difference: Centrus Energy Corp is far larger — about 5.3× Ginkgo Bioworks Holdings Inc's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, Centrus Energy Corp nearer its low. Which is the better fit depends on your goals.
| DNA | LEU | |
|---|---|---|
Market Cap | $590.53M | $3.14B |
Sector | Health | Energy |
52-Week High | $16.14 | $436.00 |
52-Week Low | $5.48 | $146.61 |
Enterprise Value | $627.78M | $2.45B |
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Centrus Energy (LEU) trades at $156.05, down 8.77% over 24 hours amid bearish technical signals. The stock shows mixed fundamentals with a high P/E of 57.96 but strong net income margin of 13.4%. Recent positive developments include a $1 billion DOE contract expansion and inclusion in the S&P SmallCap 600 index, though earnings have been inconsistent with two misses and one beat in recent quarters.
The outlook remains cautiously optimistic given strong government contracts and nuclear industry tailwinds, but elevated valuation and recent earnings volatility present risks. Analyst consensus price target of $223.14 suggests 43% upside potential, though technical indicators signal near-term bearish pressure with support at $151.
Trailing returns across standard periods
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →Centrus Energy is a leading supplier of nuclear fuel and services for the global power industry. It specializes in supplying low-enriched uranium and developing next-generation fuels for advanced nuclear reactors.
Read more on LEU →